Market Research Logo

Pancreatic Cancer - Pipeline Review, H1 2015

Introduction
Pancreatic Cancer Overview
Therapeutics Development
Pancreatic Cancer – Therapeutics under Development by Companies
Pancreatic Cancer – Therapeutics under Investigation by Universities/Institutes
Pancreatic Cancer – Pipeline Products Glance
Pancreatic Cancer – Products under Development by Companies
Pancreatic Cancer – Products under Investigation by Universities/Institutes
Pancreatic Cancer – Companies Involved in Therapeutics Development
Pancreatic Cancer – Therapeutics Assessment
Drug Profiles
Pancreatic Cancer – Recent Pipeline Updates
Pancreatic Cancer – Dormant Projects
Pancreatic Cancer – Discontinued Products
Pancreatic Cancer – Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Pancreatic Cancer, H1 2015
Number of Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Development by Companies, H1 2015 (Contd..9)
Number of Products under Development by Companies, H1 2015 (Contd..10)
Number of Products under Development by Companies, H1 2015 (Contd..11)
Number of Products under Development by Companies, H1 2015 (Contd..12)
Number of Products under Development by Companies, H1 2015 (Contd..13)
Number of Products under Development by Companies, H1 2015 (Contd..14)
Number of Products under Development by Companies, H1 2015 (Contd..15)
Number of Products under Development by Companies, H1 2015 (Contd..16)
Number of Products under Development by Companies, H1 2015 (Contd..17)
Number of Products under Development by Companies, H1 2015 (Contd..18)
Number of Products under Development by Companies, H1 2015 (Contd..19)
Number of Products under Development by Companies, H1 2015 (Contd..20)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Development by Companies, H1 2015 (Contd..13)
Products under Development by Companies, H1 2015 (Contd..14)
Products under Development by Companies, H1 2015 (Contd..15)
Products under Development by Companies, H1 2015 (Contd..16)
Products under Development by Companies, H1 2015 (Contd..17)
Products under Development by Companies, H1 2015 (Contd..18)
Products under Development by Companies, H1 2015 (Contd..19)
Products under Development by Companies, H1 2015 (Contd..20)
Products under Development by Companies, H1 2015 (Contd..21)
Products under Development by Companies, H1 2015 (Contd..22)
Products under Development by Companies, H1 2015 (Contd..23)
Products under Development by Companies, H1 2015 (Contd..24)
Products under Development by Companies, H1 2015 (Contd..25)
Products under Development by Companies, H1 2015 (Contd..26)
Products under Development by Companies, H1 2015 (Contd..27)
Products under Development by Companies, H1 2015 (Contd..28)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4)
Pancreatic Cancer – Pipeline by 3-V Biosciences, Inc., H1 2015
Pancreatic Cancer – Pipeline by 3B Pharmaceuticals GmbH, H1 2015
Pancreatic Cancer – Pipeline by 4SC AG, H1 2015
Pancreatic Cancer – Pipeline by AB Science, H1 2015
Pancreatic Cancer – Pipeline by AbbVie Inc., H1 2015
Pancreatic Cancer – Pipeline by AbGenomics International, Inc., H1 2015
Pancreatic Cancer – Pipeline by Ability Pharma, SL, H1 2015
Pancreatic Cancer – Pipeline by Adamed Sp. z o.o., H1 2015
Pancreatic Cancer – Pipeline by Adamis Pharmaceuticals Corporation, H1 2015
Pancreatic Cancer – Pipeline by Aduro BioTech, Inc., H1 2015
Pancreatic Cancer – Pipeline by Advantagene, Inc., H1 2015
Pancreatic Cancer – Pipeline by Advaxis, Inc., H1 2015
Pancreatic Cancer – Pipeline by AGV Discovery, SAS, H1 2015
Pancreatic Cancer – Pipeline by AIMM Therapeutics B.V., H1 2015
Pancreatic Cancer – Pipeline by Alchemia Limited, H1 2015
Pancreatic Cancer – Pipeline by Alethia Biotherapeutics Inc., H1 2015
Pancreatic Cancer – Pipeline by Allinky Biopharma, H1 2015
Pancreatic Cancer – Pipeline by Almac Discovery Limited, H1 2015
Pancreatic Cancer – Pipeline by Altor BioScience Corporation, H1 2015
Pancreatic Cancer – Pipeline by Ambrx, Inc., H1 2015
Pancreatic Cancer – Pipeline by Ambryx Biotechnology, Inc., H1 2015
Pancreatic Cancer – Pipeline by Amgen Inc., H1 2015
Pancreatic Cancer – Pipeline by Anavex Life Sciences Corp., H1 2015
Pancreatic Cancer – Pipeline by ANP Technologies, Inc., H1 2015
Pancreatic Cancer – Pipeline by APEIRON Biologics AG, H1 2015
Pancreatic Cancer – Pipeline by Apexigen, Inc., H1 2015
Pancreatic Cancer – Pipeline by Aphios Corporation, H1 2015
Pancreatic Cancer – Pipeline by APIM Therapeutics AS, H1 2015
Pancreatic Cancer – Pipeline by Apogenix GmbH, H1 2015
Pancreatic Cancer – Pipeline by Aposense Ltd., H1 2015
Pancreatic Cancer – Pipeline by Aptose Biosciences Inc., H1 2015
Pancreatic Cancer – Pipeline by Arch Biopartners, Inc., H1 2015
Pancreatic Cancer – Pipeline by Argon Pharma S.L., H1 2015
Pancreatic Cancer – Pipeline by Array BioPharma Inc., H1 2015
Pancreatic Cancer – Pipeline by Ascenta Therapeutics, Inc., H1 2015
Pancreatic Cancer – Pipeline by Astellas Pharma Inc., H1 2015
Pancreatic Cancer – Pipeline by AstraZeneca Plc, H1 2015
Pancreatic Cancer – Pipeline by Aurigene Discovery Technologies Limited, H1 2015
Pancreatic Cancer – Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Pancreatic Cancer – Pipeline by Axcentua Pharmaceuticals AB, H1 2015
Pancreatic Cancer – Pipeline by Azaya Therapeutics Incorporated, H1 2015
Pancreatic Cancer – Pipeline by Basilea Pharmaceutica AG, H1 2015
Pancreatic Cancer – Pipeline by Bavarian Nordic A/S, H1 2015
Pancreatic Cancer – Pipeline by Bayer AG, H1 2015
Pancreatic Cancer – Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015
Pancreatic Cancer – Pipeline by BerGenBio AS, H1 2015
Pancreatic Cancer – Pipeline by Beta Pharma, Inc., H1 2015
Pancreatic Cancer – Pipeline by Bexion Pharmaceuticals, LLC., H1 2015
Pancreatic Cancer – Pipeline by BioCancell Ltd, H1 2015
Pancreatic Cancer – Pipeline by Biogenomics Limited, H1 2015
Pancreatic Cancer – Pipeline by Biomar Microbial Technologies, H1 2015
Pancreatic Cancer – Pipeline by BioMarin Pharmaceutical Inc., H1 2015
Pancreatic Cancer – Pipeline by Biomunex Pharmaceuticals, H1 2015
Pancreatic Cancer – Pipeline by Bioncotech Therapeutics S.L., H1 2015
Pancreatic Cancer – Pipeline by Bionomics Limited, H1 2015
Pancreatic Cancer – Pipeline by BiOrion Technologies B.V., H1 2015
Pancreatic Cancer – Pipeline by Biotest AG, H1 2015
Pancreatic Cancer – Pipeline by Biothera, Inc., H1 2015
Pancreatic Cancer – Pipeline by Biouniversa s.r.l., H1 2015
Pancreatic Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2015
Pancreatic Cancer – Pipeline by Boston Biomedical, Inc., H1 2015
Pancreatic Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2015
Pancreatic Cancer – Pipeline by Calithera Biosciences, Inc., H1 2015
Pancreatic Cancer – Pipeline by Cantex Pharmaceuticals, Inc., H1 2015
Pancreatic Cancer – Pipeline by Cavion LLC, H1 2015
Pancreatic Cancer – Pipeline by Celgene Corporation, H1 2015
Pancreatic Cancer – Pipeline by Cellectis S.A., H1 2015
Pancreatic Cancer – Pipeline by Celsion Corporation, H1 2015
Pancreatic Cancer – Pipeline by Centrose Llc, H1 2015
Pancreatic Cancer – Pipeline by Ceronco Biosciences, H1 2015
Pancreatic Cancer – Pipeline by ChemoCentryx, Inc., H1 2015
Pancreatic Cancer – Pipeline by Chiome Bioscience, Inc., H1 2015
Pancreatic Cancer – Pipeline by Clovis Oncology, Inc., H1 2015
Pancreatic Cancer – Pipeline by Confluence Life Sciences, Inc., H1 2015
Pancreatic Cancer – Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Pancreatic Cancer – Pipeline by Critical Outcome Technologies Inc., H1 2015
Pancreatic Cancer – Pipeline by CritiTech, Inc., H1 2015
Pancreatic Cancer – Pipeline by CrystalGenomics, Inc., H1 2015
Pancreatic Cancer – Pipeline by CTI BioPharma Corp., H1 2015
Pancreatic Cancer – Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015
Pancreatic Cancer – Pipeline by CureTech Ltd., H1 2015
Pancreatic Cancer – Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Pancreatic Cancer – Pipeline by CytomX Therapeutics, Inc., H1 2015
Pancreatic Cancer – Pipeline by CytoVac A/S, H1 2015
Pancreatic Cancer – Pipeline by CytRx Corporation, H1 2015
Pancreatic Cancer – Pipeline by CZ BioMed Corp, H1 2015
Pancreatic Cancer – Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015
Pancreatic Cancer – Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Pancreatic Cancer – Pipeline by DEKK-TEC, Inc., H1 2015
Pancreatic Cancer – Pipeline by DiaMedica Inc., H1 2015
Pancreatic Cancer – Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015
Pancreatic Cancer – Pipeline by e-Therapeutics Plc, H1 2015
Pancreatic Cancer – Pipeline by Eisai Co., Ltd., H1 2015
Pancreatic Cancer – Pipeline by Eleison Pharmaceuticals, Inc., H1 2015
Pancreatic Cancer – Pipeline by Eli Lilly and Company, H1 2015
Pancreatic Cancer – Pipeline by Erytech Pharma SA, H1 2015
Pancreatic Cancer – Pipeline by Esperance Pharmaceuticals, Inc., H1 2015
Pancreatic Cancer – Pipeline by Etubics Corporation, H1 2015
Pancreatic Cancer – Pipeline by Exelixis, Inc., H1 2015
Pancreatic Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Pancreatic Cancer – Pipeline by FibroGen, Inc., H1 2015
Pancreatic Cancer – Pipeline by Fujifilm Corporation, H1 2015
Pancreatic Cancer – Pipeline by Fusion Antibodies Limited, H1 2015
Pancreatic Cancer – Pipeline by Ganymed Pharmaceuticals AG, H1 2015
Pancreatic Cancer – Pipeline by Genelux Corporation, H1 2015
Pancreatic Cancer – Pipeline by Genentech, Inc., H1 2015
Pancreatic Cancer – Pipeline by Genmab A/S, H1 2015
Pancreatic Cancer – Pipeline by Gilead Sciences, Inc., H1 2015
Pancreatic Cancer – Pipeline by GlaxoSmithKline Plc, H1 2015
Pancreatic Cancer – Pipeline by Globeimmune, Inc., H1 2015
Pancreatic Cancer – Pipeline by GlycoMimetics, Inc., H1 2015
Pancreatic Cancer – Pipeline by Golden Biotechnology Corp., H1 2015
Pancreatic Cancer – Pipeline by Halozyme Therapeutics, Inc., H1 2015
Pancreatic Cancer – Pipeline by Heat Biologics, Inc., H1 2015
Pancreatic Cancer – Pipeline by Helix BioPharma Corp., H1 2015
Pancreatic Cancer – Pipeline by Huabo Biopharm Co., Ltd., H1 2015
Pancreatic Cancer – Pipeline by Hutchison MediPharma Limited, H1 2015
Pancreatic Cancer – Pipeline by Igenica Biotherapeutics, Inc., H1 2015
Pancreatic Cancer – Pipeline by Ignyta, Inc., H1 2015
Pancreatic Cancer – Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015
Pancreatic Cancer – Pipeline by Immodulon Therapeutics Ltd., H1 2015
Pancreatic Cancer – Pipeline by Immune Pharmaceuticals Inc., H1 2015
Pancreatic Cancer – Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015
Pancreatic Cancer – Pipeline by Immunomedics, Inc., H1 2015
Pancreatic Cancer – Pipeline by Immunotope, Inc., H1 2015
Pancreatic Cancer – Pipeline by Immunovo BV, H1 2015
Pancreatic Cancer – Pipeline by Incuron, LLC, H1 2015
Pancreatic Cancer – Pipeline by Incyte Corporation, H1 2015
Pancreatic Cancer – Pipeline by Innopharmax Inc., H1 2015
Pancreatic Cancer – Pipeline by Inovio Pharmaceuticals, Inc., H1 2015
Pancreatic Cancer – Pipeline by Intezyne, Inc, H1 2015
Pancreatic Cancer – Pipeline by Intica Biomedical, Inc., H1 2015
Pancreatic Cancer – Pipeline by InvivoGen Therapeutics, H1 2015
Pancreatic Cancer – Pipeline by Io Therapeutics, Inc., H1 2015
List of Figures
Number of Products under Development for Pancreatic Cancer, H1 2015
Number of Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Pancreatic Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Pancreatic Cancer - Pipeline Review, H1 2015’, provides an overview of the Pancreatic Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;